�����ƽ��

Vancouver, BC, July 12, 2023 – �����ƽ�� Technologies, Canada’s largest biotechnology company, is marking its 30th year of accelerating research into cancer and other diseases by celebrating its culture of collaboration, curiosity, and discovery.

“�����ƽ�� has come a long way in the last 30 years, and by growing our talented team we are well-positioned to achieve even more in the decades to come,” said Founder, President, and CEO Dr. Allen Eaves. “Through our ever-expanding portfolio of high-quality products and services, we are supporting cancer research by making culture media for growing the stem cells of tissues that are prone to cancer, including blood, brain, breast, intestine, kidney, liver, lung, pancreas, prostate, and skin cells. This has enabled us to build unparalleled trust and confidence within the global scientific community.”

In July of 1993, Dr. Eaves remortgaged his home and obtained a government business loan to start �����ƽ�� and commercialize a reliable source of cell culture media for growing the blood-forming stem cells that can result in leukemia when they go wrong. This media, which he called MethoCult™, is now the global standard for growing blood-forming stem cells. Today, �����ƽ�� sells more than 2,500 other products, including specialized media, growth factors, monoclonal antibodies, cell separation reagents, instruments, plasticware, and contract assay services.

�����ƽ��’s story originates in the 1980s when Dr. Eaves was Director of the Vancouver-based Terry Fox Laboratory. His team was working to understand how growth factors cause blood stem cells to give rise to white and red cells, and what goes wrong in cases of leukemia. This work required cell culture media with raw materials that were carefully selected to produce reproducible growth from one experiment to the next. Soon colleagues in other institutions wanted to use this media so their results could be compared both internally and between labs in other institutions.

As a privately held company, �����ƽ�� has averaged 20 percent annual growth since its inception. This has been accomplished by putting all profits back into research, facilities, and sustainability initiatives. Ninety-seven percent of its sales are outside Canada to over 25,000 customers globally. Warehouses in Burnaby, Seattle, Grenoble, Melbourne, Singapore, and Beijing allow rapid delivery of products around the world.

With sales staff in 20 countries and distributors in 80 other countries, �����ƽ�� is a company of Scientists Helping Scientists. Of its 2,300 global employees, 1,800 are based in Canada. Deeply rooted in education, the company provides on-site and virtual training programs, as well as 21 tissue-specific weekly newsletters as part of a Science News program with more than 200,000 readers. This helps ensure scientists are trained and prepared to conduct reproducible research effectively and efficiently. For its own staff, �����ƽ�� offers over 1,700 training courses, either in-person or virtually.

“As a major biotech anchor company, �����ƽ��’s commitment to science and the advancement of research is as strong as ever, and I’m excited about the future,” Dr. Eaves said. “Our growing team will continue to play an important role in ensuring there is continued progress and innovation in life science research here in Canada and globally.”

“�����ƽ�� is a leading innovator and has played an integral role in building up Canada's life science and biotechnology ecosystem,” said Sue Paish, CEO, DIGITAL. “�����ƽ��'s commitment to scientists and to their growth in Canada and around the world is impressive. Congratulations on 30 years, and I look forward to watching what the team accomplishes in the next decade.”

About �����ƽ�� Technologies
supports life sciences research with more than 2,500 specialized reagents, tools, and services. �����ƽ�� offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.

Media Contact
For more information and to arrange an interview, contact:
Ryan-Sang Lee
Senior Manager, Corporate Communications, �����ƽ�� Technologies
public.relations@stemcell.com